SP-333

Bausch Health Americas, Inc. · Phase 1 active Small molecule

At a glance

Generic name	SP-333
Sponsor	Bausch Health Americas, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers (PHASE1)
Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) (PHASE2)
Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SP-333 CI brief — competitive landscape report
SP-333 updates RSS · CI watch RSS
Bausch Health Americas, Inc. portfolio CI